1/1
2 files

Supplementary figures - Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma

figure
posted on 29.04.2022, 08:29 by Ninad Shah, Ali Mojebi, Dieter Ayers, Shannon Cope, Sujith Dhanasiri, Faith E. Davies, Parameswaran Hari, Payal Patel, Kristen Hege, Devender Dhanda

Supplemental figure 1.  HRs of OS for ide-cel versus conventional care based on the triple- or quad-refractory population from MAMMOTH. 



Supplemental figure 2. HRs of OS for ide-cel versus conventional care based on the penta-refactory population from MAMMOTH. 


History